Optimization of methods for the genetic modification of human T cells

Immunology and Cell Biology

Volumn 93, Issue 10, 2015, Pages 896-908

  Bilal, Mahmood Y ^a   Vacaflores, Aldo ^a   Houtman, Jon C D ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; MICRORNA; PLASMID DNA; SHORT HAIRPIN RNA;

ARTICLE; CD4+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; DNA MODIFICATION; ELECTROPORATION; GENE DOSAGE; GENE TARGETING; GENETIC ALGORITHM; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; T LYMPHOCYTE ACTIVATION; ALGORITHM; BIOLOGY; CELL CULTURE; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; LENTIVIRINAE; LYMPHOCYTE ACTIVATION; RETROVIRIDAE; RNA INTERFERENCE;

ALGORITHMS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; COMPUTATIONAL BIOLOGY; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; LYMPHOCYTE ACTIVATION; MICRORNAS; RETROVIRIDAE; RNA INTERFERENCE; TRANSDUCTION, GENETIC;

EID: 84948379631     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2015.59     Document Type: Article

References (47)

1. Basson MA, Zamoyska R. Insights into T-cell development from studies using transgenic and knockout mice. Mol Biotechnol 2001; 18: 11-23.
2. Mak TW, Penninger JM, Ohashi PS. Knockout mice: a paradigm shift in modern immunology. Nat Rev Immunol 2001; 1: 11-19.
3. Jang IK, Zhang J, Chiang YJ, Kole HK, Cronshaw DG, Zou Y et al. Grb2 functions at the top of the T-cell antigen receptor-induced tyrosine kinase cascade to control thymic selection. Proc Natl Acad Sci USA 2010; 107: 10620-10625.
4. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004; 172: 2731-2738.
5. Shay T, Jojic V, Zuk O, Rothamel K, Puyraimond-Zemmour D, Feng T et al. Conservation and divergence in the transcriptional programs of the human and mouse immune systems. Proc Natl Acad Sci USA 2013; 110: 2946-2951.
6. Chicaybam L, Sodre AL, Curzio BA, Bonamino MH. An efficient low cost method for gene transfer to T lymphocytes. PLoS ONE 2013; 8: e60298.
7. Kim TK, Eberwine JH. Mammalian cell transfection: the present and the future. Anal Bioanal Chem 2010; 397: 3173-3178.
8. Ebert O, Finke S, Salahi A, Herrmann M, Trojaneck B, Lefterova P et al. Lymphocyte apoptosis: induction by gene transfer techniques. Gene Ther 1997; 4: 296-302.
9. Costello E, Munoz M, Buetti E, Meylan PR, Diggelmann H, Thali M. Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors. Gene Ther 2000; 7: 596-604.
10. Cavalieri S, Cazzaniga S, Geuna M, Magnani Z, Bordignon C, Naldini L et al. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 2003; 102: 497-505.
11. Cooray S, Howe SJ, Thrasher AJ. Retrovirus and lentivirus vector design and methods of cell conditioning. Methods Enzymol 2012; 507: 29-57.
12. Charrier S, Dupre L, Scaramuzza S, Jeanson-Leh L, Blundell MP, Danos O et al. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients. Gene Ther 2007; 14: 415-428.
13. Brenner S, Malech HL. Current developments in the design of onco-retrovirus and lentivirus vector systems for hematopoietic cell gene therapy. Biochim Biophys Acta 2003; 1640: 1-24.
14. Ramezani A, Hawley TS, Hawley RG. Stable gammaretroviral vector expression during embryonic stem cell-derived in vitro hematopoietic development. Mol Ther 2006; 14: 245-254.
15. Bilal MY, Zhang EY, Dinkel B, Hardy D, Yankee TM, Houtman JC. GADS is required for TCR-mediated calcium influx and cytokine release, but not cellular adhesion, in human T cells. Cell Signal 2015; 27: 841-850.
16. Bilal MY, Houtman JC. GRB2 nucleates T cell receptor-mediated LAT clusters that control PLC-gamma1 activation and cytokine production. Front Immunol 2015; 6: 141.
17. Kesireddy V, van der Ven PF, Furst DO. Multipurpose modular lentiviral vectors for RNA interference and transgene expression. Mol Biol Rep 2010; 37: 2863-2870.
18. Keck K, Volper EM, Spengler RM, Long DD, Chan CY, Ding Y et al. Rational design leads to more potent RNA interference against hepatitis B virus: factors effecting silencing efficiency. Mol Ther 2009; 17: 538-547.
19. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol 2004; 22: 326-330.
20. Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet 2011; 12: 329-340.
21. McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 2008; 105: 5868-5873.
22. Boden D, Pusch O, Silbermann R, Lee F, Tucker L, Ramratnam B. Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res 2004; 32: 1154-1158.
23. Zhang M, Ma Z, Selliah N, Weiss G, Genin A, Finkel TH et al. The impact of Nucleofection(R) on the activation state of primary human CD4 T cells. J Immunol Methods 2014; 408: 123-131.
24. Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, Shpall EJ et al. Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp 2013; 72: e50070.
25. Ellis BL, Potts PR, Porteus MH. Creating higher titer lentivirus with caffeine. Hum Gene Ther 2011; 22: 93-100.
26. Olsen JC, Sechelski J. Use of sodium butyrate to enhance production of retroviral vectors expressing CFTR cDNA. Hum Gene Ther 1995; 6: 1195-1202.
27. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014; 346: 1258096.
28. Bhaya D, Davison M, Barrangou R. CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu Rev Genet 2011; 45: 273-297.
29. Zheng Q, Cai X, Tan MH, Schaffert S, Arnold CP, Gong X et al. Precise gene deletion and replacement using the CRISPR/Cas9 system in human cells. Biotechniques 2014; 57: 115-124.
30. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 2013; 153: 910-918.
31. Mandal PK, Ferreira LM, Collins R, Meissner TB, Boutwell CL, Friesen M et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 2014; 15: 643-652.
32. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK et al. High-frequency offtarget mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 2013; 31: 822-826.
33. Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 2013; 31: 827-832.
34. Pattanayak V, Lin S, Guilinger JP, Ma E, Doudna JA, Liu DR. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol 2013; 31: 839-843.
35. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013; 339: 819-823.
36. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012; 337: 816-821.
37. Romero F, Ramos-Morales F, Dominguez A, Rios RM, Schweighoffer F, Tocque B et al. Grb2 and its apoptotic isoform Grb3-3 associate with heterogeneous nuclear ribonucleoprotein C, and these interactions are modulated by poly(U) RNA. J Biol Chem 1998; 273: 7776-7781.
38. Das G, Henning D, Reddy R. Structure, organization, and transcription of Drosophila U6 small nuclear RNA genes. J Biol Chem 1987; 262: 1187-1193.
39. Wise TG, Schafer DJ, Lambeth LS, Tyack SG, Bruce MP, Moore RJ et al. Characterization and comparison of chicken U6 promoters for the expression of short hairpin RNAs. Anim Biotechnol 2007; 18: 153-162.
40. Roelz R, Pilz IH, Mutschler M, Pahl HL. Of mice and men: human RNA polymerase III promoter U6 is more efficient than its murine homologue for shRNA expression from a lentiviral vector in both human and murine progenitor cells. Exp Hematol 2010; 38: 792-797.
41. Makinen PI, Koponen JK, Karkkainen AM, Malm TM, Pulkkinen KH, Koistinaho J et al. Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain. J Gene Med 2006; 8: 433-441.
42. Lebbink RJ, Lowe M, Chan T, Khine H, Wang X, McManus MT. Polymerase II promoter strength determines efficacy of microRNA adapted shRNAs. PLoS ONE 2011; 6: e26213.
43. Pan C, Kumar C, Bohl S, Klingmueller U, Mann M. Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions. Mol Cell Proteomics 2009; 8: 443-450.
44. Kaur G, Dufour JM. Cell lines: Valuable tools or useless artifacts. Spermatogenesis 2012; 2: 1-5.
45. Tremblay MM, Houtman JC. TCR-mediated functions are enhanced in activated peripheral blood T cells isolated from leucocyte reduction systems. J Immunol Methods 2014; 416: 137-145.
46. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS et al. Lentivirusdelivered stable gene silencing by RNAi in primary cells. RNA 2003; 9: 493-501.
47. Bartelt RR, Cruz-Orcutt N, Collins M, Houtman JC. Comparison of T cell receptorinduced proximal signaling and downstream functions in immortalized and primary T cells. PLoS ONE 2009; 4: e5430.